Royalty Pharma reported second quarter Portfolio Receipts of $773 million, a 6% increase year-over-year, driven by strong growth in its core Royalty Receipts. The company's performance led it to raise its full-year 2026 guidance for the second time this year.
Key Highlights
- Second quarter Portfolio Receipts grew 6% to $773 million, surpassing the consensus estimate of $758.9 million.
- Royalty Receipts, the primary component of the topline, increased 14% to $768 million, fueled by strong performance from therapies including Tremfya, Voranigo, Imdelltra, and Evrysdi.
- The company raised its full-year 2026 guidance for Portfolio Receipts to a new range of $3.40 billion to $3.50 billion, up from the prior range of $3.325 billion to $3.450 billion.